Imidafenacin

Imidafenacin
Clinical data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.216.585
Chemical and physical data
FormulaC20H21N3O
Molar mass319.408 g·mol−1
3D model (JSmol)
  • CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N
  • InChI=1S/C20H21N3O/c1-16-22-13-15-23(16)14-12-20(19(21)24,17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,13,15H,12,14H2,1H3,(H2,21,24) ☒N
  • Key:SQKXYSGRELMAAU-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Imidafenacin (INN) is a urinary antispasmodic of the anticholinergic class.[1] It is used for the treatment of urinary incontinence and related bladder issues, especially in patients with benign prostatic hyperplasia or who have had prostate surgery. Unlike most related drugs, it is orally active but still shows a rapid onset of action, which makes it more convenient to administer.[2][3][4]

References

  1. ^ Kobayashi F, Yageta Y, Segawa M, Matsuzawa S (2007). "Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland". Arzneimittelforschung. 57 (2): 92–100. doi:10.1055/s-0031-1296589. PMID 17396619. S2CID 21636454.
  2. ^ Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Grossmann NC, Laukhtina E, Schuettfort VM, Aydh A, Sari Motlagh R, König F, Roehrborn CG, Katayama S, Rajwa P, Hajebrahimi S, Shariat SF. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol Focus. 2022 Jul;8(4):1072-1089. doi:10.1016/j.euf.2021.08.011 PMID 34563481
  3. ^ Su YT, Chen HL, Teoh JY, Chan VW, Wu WJ, Lee HY. Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients - a network meta-analysis. BMC Urol. 2023 Oct 3;23(1):154. doi:10.1186/s12894-023-01327-1 PMID 37789333
  4. ^ Lee JH, Goh HJ, Lee K, Choi DW, Lee KM, Kim S. Efficacy and safety evaluation of imidafenacin administered twice daily for continency recovery following radical prostatectomy in prostate cancer patients: Prospective open-label case-controlled randomized trial. Investig Clin Urol. 2024 Sep;65(5):466-472. doi:10.4111/icu.20240129 PMID 39249919
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.